A network meta-analysis of 18 trials found that adding astragalus-containing Chinese patent medicines to standard Western medicine treatments was associated with greater improvements in heart failure markers compared to Western medicine alone, but the included studies had significant quality limitations that weaken confidence in these findings.
Researchers conducting this network meta-analysis synthesized data from 18 randomized controlled trials spanning 1,584 heart failure patients to compare the effectiveness of various astragalus-containing traditional Chinese medicines (TCMs) when added to Western medicine treatment versus Western medicine alone. The analysis examined 16 different proprietary Chinese formulations, each combined with standard cardiac medications. The researchers used systematic database searching through May 2025 and applied standard quality assessment tools to evaluate bias risk in the included studies.
Across multiple clinical endpoints, the analysis identified different formulations as "top performers." Astragalus Granule combined with Western medicine ranked best for improving overall clinical efficacy rates and reducing B-type natriuretic peptide (BNP) levels, a marker of cardiac stress. For functional capacity, Qiangxin Capsule plus Western medicine showed the strongest association with improvements on six-minute walk testing. On ejection fraction (a measure of heart pumping efficiency), Xinlishen Compound combined with Western medicine ranked highest, while Qili Qiangxin Capsule plus Western medicine was associated with the greatest reductions in left ventricular end-diastolic diameter (a structural heart measurement). Quality of life metrics favored Yangxin Tongmai II Prescription when added to standard therapy.
These findings suggest a consistent pattern: adding an astragalus-containing formula to existing Western medicine protocols was associated with better outcomes across tested measures than Western medicine treatment alone. However, the authors explicitly acknowledged a critical limitation: the included trials were heterogeneous in design and of mixed quality. The studies used different control groups, measured outcomes differently, and varied in their adherence to rigorous trial methodology. The authors emphasized that their conclusions "require further validation through well-designed randomized double-blind controlled trials."
This caveat is important context. Network meta-analyses synthesize indirect evidence and depend heavily on the quality of underlying studies. When source trials lack rigorous blinding, standardized protocols, or adequate reporting of methods, downstream conclusions become less reliable. The authors' transparency about these limitations reflects appropriate scientific caution rather than confidence in definitive efficacy.
This analysis does not establish that astragalus-containing Chinese medicines treat or cure heart failure. The research shows associations between adding these formulations to existing treatment and improvements in measurable cardiac parameters, but cannot isolate astragalus itself as the active ingredient or mechanism.
If you have heart failure, your treatment should remain coordinated with your cardiologist. Standard Western medicine for heart failure, including ACE inhibitors, beta-blockers, and diuretics, has decades of rigorous trial evidence supporting their use. Any consideration of adding traditional Chinese formulations would need individual medical evaluation, as TCMs can interact with medications and may not be appropriate for all patients or disease stages.
The variability in which formulations "ranked best" across different outcomes suggests that astragalus-containing products are not interchangeable. If research interest in this area continues, future studies should isolate specific formulations, use standardized dosing, employ rigorous blinding methods, and pre-specify outcomes before analyzing data.
For researchers and practitioners interested in cardiac applications of herbal medicine, this analysis provides a useful map of where evidence density exists (astragalus formulations have been studied) and where it's lacking (most underlying trials were not high-quality). This can help identify which combinations merit more rigorous future investigation.
| Attribute | Details |
|---|---|
| Study type | Systematic review and network meta-analysis |
| Sample size | 1,584 patients across 18 randomized controlled trials |
| Comparisons | 16 different astragalus-containing Chinese patent medicines, each combined with Western medicine vs. Western medicine alone |
| Primary outcomes | Clinical efficacy rate, six-minute walk test, BNP levels, NT-proBNP levels, left ventricular ejection fraction, left ventricular end-diastolic diameter, Minnesota Heart Failure Quality of Life Questionnaire scores |
| Journal | Medicine |
| Publication year | 2025 |
| PubMed ID | 42216323 |
| Limitations | Mixed quality of included studies, lack of standardized protocols, heterogeneous outcome reporting, absence of double-blind methodology in many trials |
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.